ReviewBladder cancer (Amsterdam, Netherlands)2018
Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer.
Review in Bladder cancer (Amsterdam, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic significance of circulating tumor DNA in urothelial carcinoma patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Predicting inguinal lymph node metastasis in penile squamous cell carcinoma, from imaging, molecular biomarkers to multimodal AI: a narrative review.Translational andrology and urology · 2026Review
- Circulating tumor DNA as a prognostic and monitoring biomarker in urothelial cancers.Frontiers in oncology · 2026Review
- Liquid Biopsy: Current advancements in clinical practice for bladder cancer.The journal of liquid biopsy · 2025Review
- Monitoring circulating tumor DNA by recurrent hotspot mutations in bladder cancer.BJC reports · 2025Article
- Circulating Tumor Cells in Cancer Diagnosis, Therapy, and Theranostics Applications: An Overview of Emerging Materials and Technologies.Current pharmaceutical design · 2025Review
- Circulating tumor DNA: a revolutionary approach for early detection and personalized treatment of bladder cancer.Frontiers in pharmacology · 2025Review
- An Investigation into Cell-Free DNA in Different Common Cancers.Molecular biotechnology · 2024Review
- Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2024Article
- Examining longitudinal markers of bladder cancer recurrence through a semiautonomous machine learning system for quantifying specimen atypia from urine cytology.Cancer cytopathology · 2023Article
- Advanced Peptide Nanomedicines for Bladder Cancer Theranostics.Frontiers in chemistry · 2022Review
- Review
- Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker.International journal of molecular sciences · 2021Review
- Mutation differences in circulating tumor DNAs from non-small cell lung cancer patients between Uygur and Han populations.Medicine · 2021Article
- Review of non-invasive urinary biomarkers in bladder cancer.Translational cancer research · 2020Review
- The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.The oncologist · 2019Article
- Can urinary biomarkers replace cystoscopy?World journal of urology · 2019Review
- [Follow-up surveillance of muscle-invasive urinary bladder cancer after curative treatment].Der Urologe. Ausg. A · 2019Article
- The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder.World journal of urology · 2019Review
- Detection of Circulating Tumor DNA with a Single-Molecule Sequencing Analysis Validated for Targeted and Immunotherapy Selection.Molecular diagnosis & therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in DNA profiling techniques have enabled sensitive detection of tumor-associated genomic aberrations in peripheral blood. This type of minimally-invasive molecular interrogation has the potential to guide subsequent treatment selection. The potential utility of ctDNA in bladder cancer (BC) is bolstered by the high somatic mutation rate, meaning that very small numbers of genes or target regions can be informative. First reports indicate that analysis of ctDNA may represent a sensitive method for disease surveillance in patients with different stages of BC. Moreover, recent evidence suggests that ctDNA analysis reveals previously unknown genomic alterations in metastatic patients. Since some of these gene alterations represent therapeutic targets, ctDNA analysis provides an attractive tool to guide individualized therapy in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.